CHD

Featured Article

CVD in Rheumatoid Arthritis: How Can We Improve Diagnosis?

CVD in Rheumatoid Arthritis: How Can We Improve Diagnosis?

Patients with rheumatoid arthritis have a significantly higher risk for cardiovascular disease, increasing their risk for morbidity and mortality.

Latest Features

CVD in Rheumatoid Arthritis: How Can We Improve Diagnosis?

CVD in Rheumatoid Arthritis: How Can We Improve Diagnosis?

Patients with rheumatoid arthritis have a significantly higher risk for cardiovascular disease, increasing their risk for morbidity and mortality.

Identifying At-Risk Patients Using Coronary Artery Calcium Scores

Identifying At-Risk Patients Using Coronary Artery Calcium Scores

Researchers argue that elevated coronary artery calcium scores increase the risk of adverse cardiovascular events even in young patients.

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Evidence is lacking to support oxygen therapy for acute myocardial infarction.

Coronary Heart Disease in HIV/AIDS: Confronting 2 Major Health Issues

Coronary Heart Disease in HIV/AIDS: Confronting 2 Major Health Issues

A review of cardiovascular disease burden, particularly coronary heart disease, in HIV/AIDS.

Reducing the Progression of Coronary Heart Disease With Estradiol

Reducing the Progression of Coronary Heart Disease With Estradiol

In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.

Latest News

Empagliflozin May Reduce Cardiovascular Mortality in T2D With LVH

Empagliflozin May Reduce Cardiovascular Mortality in T2D With LVH

For patients with T2D and left ventricular hypertrophy, empagliflozin reduced the risk for cardiovascular death vs placebo.

Higher Exposure to CVD Risk Factors in Women vs Men Who Have Diabetes

Higher Exposure to CVD Risk Factors in Women vs Men Who Have Diabetes

Compared with men, women in whom diabetes develops experience greater changes in the cumulative burden of cardiovascular risk factors from young to middle-age adulthood, which may contribute to a higher risk for CVD events.

Aspirin for Cardiovascular Primary Prevention Tied to Major Bleeding

Aspirin for Cardiovascular Primary Prevention Tied to Major Bleeding

Aspirin may be linked to an increased risk of major bleeding and decreased risk of cardiovascular events in individuals without cardiovascular disease.

Treating Albuminuria Reduces Cardiovascular Events in Type 2 Diabetes

Treating Albuminuria Reduces Cardiovascular Events in Type 2 Diabetes

Suppressing albuminuria should be an important target of therapy, according to investigators.

Glycemic Variability May Predict Incident Cardiovascular Disease, Mortality

Glycemic Variability May Predict Incident Cardiovascular Disease, Mortality

The researchers' findings contribute to a growing body of evidence regarding the prognostic value of glycemic variability.

Hormone Therapy May Affect Cardiovascular Profiles in Transgender Persons

Hormone Therapy May Affect Cardiovascular Profiles in Transgender Persons

Investigators evaluated whether treatment with one year of oral or transdermal administration of estrogen plus cyproterone and transdermal or intramuscular application of testosterone caused changes in serum lipids and blood pressure.

DPP-4 inhibition Potentially Reduces Atherogenesis in Some PLWHIV

DPP-4 inhibition Potentially Reduces Atherogenesis in Some PLWHIV

Treatment with sitagliptin had no effect on soluble CD14 when given to participants with virally suppressed HIV infection.

Early Age at BMI Rebound May Be a Risk Factor for Cardiometabolic Disorders

Early Age at BMI Rebound May Be a Risk Factor for Cardiometabolic Disorders

Children with normal timing of BMI peak who experienced an early adiposity rebound or without any BMI decline after infancy appear to have the highest risk of developing an adverse cardiometabolic profile in adolescence.

CXCR4 Lower in Women With HIV and Subclinical Cardovascular Disease

CXCR4 Lower in Women With HIV and Subclinical Cardovascular Disease

In women with HIV and subclinical cardiovascular disease (CVD), CXCR4 expression in non-classical monocytes is significantly lower.

Does Rivaroxaban Plus Aspirin Prevent Early Coronary Bypass Graft Occlusion?

Does Rivaroxaban Plus Aspirin Prevent Early Coronary Bypass Graft Occlusion?

The combination of rivaroxaban 2.5 mg twice daily plus aspirin was associated with similar reductions in major adverse cardiovascular events as observed in the larger COMPASS trial.

Sign Up for Free e-Newsletters